Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Ltd (DRREDDY) is scheduled to report results on 23 Oct 2026. Dr Reddys Laboratories Ltd last reported results for the quarter ended Jun 2026, with sales of ₹8,100 crore and net profit of ₹436 crore. The stock last traded at ₹1,197, a market capitalisation of ₹99,911 crore, on a P/E of 31.0. Over the past 52 weeks the stock has ranged between ₹1,080 and ₹1,415. Figures are as of 9 Oct 2026 and are not real time.
Dr Reddys Laboratories Ltd share price and key metrics
- Current price
- ₹1,197
- Market cap
- ₹99,911 cr
- Stock P/E
- 31.0
- Book value
- ₹454
- ROE
- 11.2%
- ROCE
- 13.0%
- Dividend yield
- 0.67%
- 52w high / low
- 1415/1080
Metrics as of 9 Oct 2026. Not real time.
Track Dr Reddys Laboratories Ltd
Cruxal reads every Dr Reddys Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Dr Reddys Laboratories Ltd growth and returns
- 10 Years
- 8%
- 5 Years
- 12%
- 3 Years
- 11%
- TTM
- -1%
- 10 Years
- 7%
- 5 Years
- 15%
- 3 Years
- -4%
- TTM
- -43%
- 10 Years
- 7%
- 5 Years
- 4%
- 3 Years
- 3%
- 1 Year
- -4%
- 10 Years
- 15%
- 5 Years
- 16%
- 3 Years
- 16%
- Last Year
- 11%
Dr Reddys Laboratories Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹8,100 cr, down 5.5% from ₹8,572 cr a year earlier. Net profit was ₹436 cr, down 69.1% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 8,038 | 8,381 | 8,528 | 8,572 | 8,828 | 8,753 | 7,546 | 8,100 |
| Expenses | 5,962 | 6,108 | 6,530 | 6,398 | 6,818 | 6,866 | 7,164 | 7,240 |
| Operating profit | 2,076 | 2,273 | 1,998 | 2,174 | 2,010 | 1,888 | 382 | 860 |
| OPM % | 26% | 27% | 23% | 25% | 23% | 22% | 5% | 11% |
| Other income | 314 | 154 | 528 | 290 | 330 | 271 | 480 | 356 |
| Interest | 76 | 82 | 66 | 83 | 91 | 94 | 106 | 126 |
| Depreciation | 397 | 471 | 455 | 476 | 505 | 521 | 557 | 537 |
| Profit before tax | 1,917 | 1,874 | 2,005 | 1,905 | 1,745 | 1,543 | 200 | 553 |
| Tax % | 30% | 25% | 21% | 26% | 23% | 23% | -11% | 21% |
| Net profit | 1,342 | 1,404 | 1,587 | 1,410 | 1,337 | 1,190 | 221 | 436 |
| EPS (₹) | 15.05 | 16.94 | 19.09 | 16.99 | 16.14 | 14.50 | 2.65 | 5.32 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Dr Reddys Laboratories Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 14,196 | 14,281 | 15,448 | 17,517 | 19,048 | 21,545 | 24,670 | 28,011 | 32,644 | 33,700 | 33,228 |
| Operating profit | 2,472 | 2,351 | 3,178 | 2,477 | 3,874 | 3,768 | 6,470 | 7,933 | 8,547 | 6,454 | 5,140 |
| OPM % | 17% | 16% | 21% | 14% | 20% | 17% | 26% | 28% | 26% | 19% | 15% |
| Net profit | 1,292 | 947 | 1,950 | 2,026 | 1,952 | 2,182 | 4,507 | 5,578 | 5,725 | 4,158 | 3,183 |
| EPS (₹) | 15.59 | 11.41 | 23.49 | 24.38 | 23.47 | 26.23 | 54.14 | 66.87 | 67.77 | 50.27 | 38.61 |
TTM is the trailing twelve months to the most recent quarter.
Dr Reddys Laboratories Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 84 |
| Reserves | 12,179 | 12,489 | 13,941 | 15,516 | 17,558 | 19,129 | 23,203 | 28,171 | 33,466 | 37,808 |
| Borrowings | 4,918 | 5,071 | 3,838 | 2,210 | 3,031 | 3,384 | 1,347 | 2,002 | 4,677 | 7,734 |
| Other liabilities | 4,474 | 4,706 | 4,557 | 5,414 | 5,915 | 7,149 | 7,576 | 8,523 | 9,797 | 10,951 |
| Total liabilities | 21,654 | 22,349 | 22,418 | 23,223 | 26,588 | 29,746 | 32,209 | 38,780 | 48,023 | 56,577 |
| Fixed assets | 6,931 | 6,968 | 7,191 | 6,850 | 8,206 | 8,122 | 9,219 | 10,426 | 18,226 | 22,063 |
| CWIP | 3,324 | 3,470 | 2,934 | 1,535 | 1,565 | 1,293 | 1,030 | 1,419 | 2,466 | 1,460 |
| Investments | 2,110 | 2,298 | 2,587 | 2,678 | 2,212 | 2,616 | 4,986 | 4,930 | 4,051 | 5,285 |
| Other assets | 9,290 | 9,612 | 9,707 | 12,160 | 14,605 | 17,715 | 16,974 | 22,004 | 23,280 | 27,768 |
| Total assets | 21,654 | 22,349 | 22,418 | 23,223 | 26,588 | 29,746 | 32,209 | 38,780 | 48,023 | 56,577 |
As reported by the company. Total assets equal total liabilities by construction.
Dr Reddys Laboratories Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 2,144 | 1,803 | 2,870 | 2,984 | 3,570 | 2,811 | 5,888 | 4,543 | 4,643 | 5,674 |
| Cash from investing | -1,890 | -1,483 | -769 | -495 | -2,255 | -2,565 | -4,109 | -4,034 | -5,785 | -6,425 |
| Cash from financing | -369 | -444 | -2,133 | -2,516 | -30 | -242 | -2,686 | -376 | 1,891 | 829 |
| Net cash flow | -114 | -124 | -31 | -27 | 1,286 | 3 | -907 | 133 | 749 | 78 |
| Free cash flow | 926 | 713 | 2,248 | 2,412 | 2,323 | 1,238 | 4,009 | 1,908 | 1,327 | 2,004 |
| CFO / operating profit | 110% | 88% | 106% | 149% | 107% | 94% | 108% | 83% | 78% | 109% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Dr Reddys Laboratories Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 9% | 8% | 13% | 11% | 16% | 14% | 27% | 27% | 23% | 13% |
| Debtor days | 98 | 104 | 94 | 105 | 95 | 113 | 107 | 105 | 101 | 110 |
| Inventory days | 282 | 263 | 273 | 230 | 273 | 250 | 232 | 283 | 260 | 228 |
| Days payable | 104 | 121 | 111 | 100 | 109 | 111 | 108 | 116 | 97 | 91 |
| Cash conversion cycle | 275 | 246 | 256 | 235 | 259 | 252 | 231 | 271 | 264 | 247 |
| Working capital days | -14 | 39 | 65 | 59 | 57 | 61 | 84 | 118 | 69 | 68 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Dr Reddys Laboratories Ltd shareholding pattern
Promoters held 26.63% at Jun 2026, broadly unchanged since Jun 2025. FIIs 20.67% and DIIs 31.75%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 26.64% | 26.64% | 26.64% | 26.64% | 26.64% | 26.64% | 26.63% | 26.63% |
| FIIs | 27.53% | 26.85% | 25.75% | 25.33% | 24.69% | 22.34% | 21.14% | 20.67% |
| DIIs | 21.48% | 22.89% | 25.63% | 26.73% | 27.99% | 30.44% | 30.72% | 31.75% |
| Public | 24.20% | 23.46% | 21.69% | 21.04% | 20.45% | 20.33% | 21.27% | 20.76% |
| No. of shareholders | 3,10,403 | 4,03,669 | 4,59,605 | 4,51,929 | 4,49,216 | 4,55,243 | 4,49,665 | 4,46,086 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When is Dr Reddys Laboratories Ltd’s next results date?
Dr Reddys Laboratories Ltd’s next results are scheduled for 23 Oct 2026.
- Earnings resultsConsider and approve unaudited standalone and consolidated financial results for the quarter ending September 30, 2026
See the full results calendar for every Indian company reporting in the next 30 days.
Dr Reddys Laboratories Ltd corporate filings
- Dr Reddys Laboratories Discloses Regulatory Filing Under SEBI LODR RegulationsCompany Updatelow impact
Cruxal's analysis: On October 8, 2026, Dr Reddys Laboratories filed a regulatory disclosure under SEBI…
Read the full analysis - Dr. Reddy's Laboratories to announce Q2FY27 results on October 23, 2026; upcoming earnings call indicates focus on quarterly performanceCompany Updatemedium impact
Cruxal's analysis: Dr. Reddy's Laboratories Ltd. has scheduled its Q2FY27 results release for October 23…
Read the full analysis - Certificate under Regulation 74(5) of SEBI (Depositories & Participants) Regulations, 2018Company Updatelow impact
- Dr Reddys Laboratories Discloses Regulatory Filing Under SEBI LODR RegulationsCompany Updatelow impact
Cruxal's analysis: On October 3, 2026, Dr Reddys Laboratories filed a regulatory disclosure under SEBI…
Read the full analysis - Closure of Trading windowInsider Trading / SASTlow impact
- Dr. Reddy's Laboratories schedules Board Meeting for Q2 FY27 financial results on October 23, 2026Board Meetinglow impact
Cruxal's analysis: Dr. Reddy's Laboratories Limited has announced that a meeting of its Board of Directors…
Read the full analysis - Dr. Reddy's Laboratories announces upcoming analyst and investor meetingCompany Updatelow impact
Cruxal's analysis: Dr. Reddy's Laboratories has issued an intimation regarding a scheduled analyst and…
Read the full analysis - Dr. Reddy's Laboratories Ltd: Routine Regulatory Disclosure under SEBI LODRCompany Updatelow impact
Cruxal's analysis: Dr. Reddy's Laboratories has filed a routine disclosure under Regulation 30 of the SEBI…
Read the full analysis - Dr. Reddy's Laboratories issues clarification regarding Regulation 30 disclosureCompany Updatelow impact
Cruxal's analysis: Dr. Reddy's Laboratories has filed a clarification under Regulation 30 of the SEBI (LODR)…
Read the full analysis - Dr. Reddy's Laboratories Ltd: Disclosure of newspaper publication regarding financial resultsCompany Updatelow impact
Cruxal's analysis: Dr. Reddy's Laboratories has filed a routine disclosure confirming the publication of its…
Read the full analysis - Dr. Reddy's Laboratories Ltd: Routine Regulatory Disclosure under SEBI LODRCompany Updatelow impact
Cruxal's analysis: Dr. Reddy's Laboratories has filed a routine disclosure under Regulation 30 of the SEBI…
Read the full analysis - Dr. Reddy's Laboratories announces routine allotment of employee stock optionsCompany Updatelow impact
Cruxal's analysis: Dr. Reddy's Laboratories has filed a disclosure regarding the allotment of employee stock…
Read the full analysis - Dr. Reddy's Laboratories announces intimation of analyst/investor meetingCompany Updatelow impact
Cruxal's analysis: Dr. Reddy's Laboratories has issued a formal intimation regarding an upcoming…
Read the full analysis - Dr. Reddy's Laboratories announces routine allotment of employee stock optionsCompany Updatelow impact
Cruxal's analysis: Dr. Reddy's Laboratories has filed a disclosure regarding the allotment of equity shares…
Read the full analysis - Dr. Reddy's Laboratories Ltd: Disclosure of newspaper publication regarding statutory filingsCompany Updatelow impact
Cruxal's analysis: Dr. Reddy's Laboratories has released copies of newspaper advertisements as part of its…
Read the full analysis - Dr. Reddy's Laboratories Ltd: Routine Regulatory Disclosure under SEBI (LODR) RegulationsCompany Updatelow impact
Cruxal's analysis: Dr. Reddy's Laboratories has filed a routine disclosure under Regulation 30 of the SEBI…
Read the full analysis - Dr. Reddy's Laboratories Ltd: Routine Regulatory Disclosure under SEBI LODRCompany Updatelow impact
Cruxal's analysis: Dr. Reddy's Laboratories has filed a routine disclosure under Regulation 30 of the SEBI…
Read the full analysis - ICICI Prudential Mutual Fund crosses 5% shareholding threshold in Dr. Reddy's Laboratories Ltd.Insider Trading / SASTlow impact
Cruxal's analysis: ICICI Prudential Mutual Fund has acquired 7,12,884 equity shares of Dr. Reddy's…
Read the full analysis - Dr. Reddy's Laboratories Announces Resignation of CEO, API and ServicesCompany Updatemedium impact
Cruxal's analysis: Dr. Reddy's Laboratories Limited has formally disclosed the resignation of Mr. Deepak…
Read the full analysis - Dr. Reddy's Laboratories Ltd: Routine Regulatory Disclosure under SEBI LODRCompany Updatelow impact
Cruxal's analysis: Dr. Reddy's Laboratories has filed a routine disclosure under Regulation 30 of the SEBI…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.